{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:13:33Z","timestamp":1788902013622,"version":"build-2803163510"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>\n                    A 72\u2011year\u2011old man with low\u2011to\u2011moderate\u2011grade esophageal squamous cell carcinoma (ESCC) who had previously undergone surgery, thoracic radiotherapy, chemotherapy, and immunotherapy was found to have bilateral cervical lymph\u2011node metastases on\n                    <jats:sup>18<\/jats:sup>\n                    F\u2011FDG PET\/CT. The patient then received two cycles of\n                    <jats:sup>177<\/jats:sup>\n                    Lu\u2011FAP\u20112286 in combination with camrelizumab. The\n                    <jats:sup>68<\/jats:sup>\n                    Ga-FAP-2286 PET\/CT imaging demonstrated significant diminution of the lesions, with no severe adverse reactions observed.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006591","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:01:27Z","timestamp":1785416487000},"page":"931-933","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Combined 177Lu-FAP-2286 Therapy and Immunotherapy in Metastatic Esophageal Squamous Cell Carcinoma"],"prefix":"10.1097","volume":"51","author":[{"given":"Lixian","family":"Mou","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province"},{"name":"Laboratory for Targeted Radiopharmaceuticals Creation"},{"name":"Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yemei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province"},{"name":"Laboratory for Targeted Radiopharmaceuticals Creation"},{"name":"Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province"},{"name":"Laboratory for Targeted Radiopharmaceuticals Creation"},{"name":"Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlu","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province"},{"name":"Laboratory for Targeted Radiopharmaceuticals Creation"},{"name":"Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4088-7649","authenticated-orcid":false,"given":"Yue","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province"},{"name":"Laboratory for Targeted Radiopharmaceuticals Creation"},{"name":"Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"R1-20260908","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1007\/s11010-025-05226-x","article-title":"Effects of FAP+\u00a0fibroblasts on cell proliferation migration and immunoregulation of esophageal squamous carcinoma cells through the CXCL12\/CXCR4 axis","volume":"480","author":"Duan","year":"2025","journal-title":"Mol Cell Biochem"},{"key":"R2-20260908","doi-asserted-by":"crossref","first-page":"123679","DOI":"10.1016\/j.biomaterials.2025.123679","article-title":"Precision targeted cancer-associated fibroblast nano-regulator enhanced chemo-immunotherapy for triple-negative breast cancer","volume":"326","author":"Xian","year":"2026","journal-title":"Biomaterials"},{"key":"R3-20260908","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1056\/NEJMra035010","article-title":"Esophageal cancer","volume":"349","author":"Enzinger","year":"2003","journal-title":"N Engl J Med"},{"key":"R4-20260908","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.120.259192","article-title":"Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using (177)Lu-FAP-2286: first-in-humans results","volume":"63","author":"Baum","year":"2022","journal-title":"J Nucl Med"},{"key":"R5-20260908","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/RLU.0000000000006271","article-title":"177Lu-FAP-2286 therapy for advanced lung adenocarcinoma with multiple metastases: a promising last-line treatment option","volume":"51","author":"Lin","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R6-20260908","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1007\/s00259-025-07545-z","article-title":"[(177)Lu]Lu-FAP-2286 therapy in a case of gastric adenocarcinoma with peritoneal metastasis","volume":"53","author":"Wang","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R7-20260908","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1007\/s00259-024-06864-x","article-title":"Evaluating the efficacy of [(177)Lu]Lu-FAP-2286 in combination therapy for metastatic breast cancer","volume":"51","author":"Kuyumcu","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R8-20260908","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1007\/s00259-023-06211-6","article-title":"Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition","volume":"50","author":"Zboralski","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006591","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:01:06Z","timestamp":1788901266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":8,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006591","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"2026-05-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}